Clinical trials
Patients With Advanced Solid Tumors clinical trials
Below are recruiting patients with advanced solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,061 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT06782425RecruitingPhase 1
Cell therapy for advanced stomach cancer with Claudin18.2 protein
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
Anyang, HenanAges 18–75 - NCT06563375RecruitingPhase 1
Testing NP-101 for advanced solid tumors
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
Houston, TexasAges 18 years+ - NCT06947811RecruitingPhase 1/Phase 2
Almonertinib plus Palbociclib for KRAS-mutated solid tumors
This trial tests a combination of two targeted drugs, Almonertinib and Palbociclib, for people with advanced solid tumors that have a KRAS mutation. It aims to see if this new combination can shrink tumors or slow their growth, and it may be an option if your cancer has not responded to other treatments.
Guangzhou, GuangdongAges 18–70 - NCT07372625RecruitingPhase 1
How rezatapopt affects common drugs in advanced solid tumors with TP53 Y220C mutation
This trial tests how rezatapopt changes the way your body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C gene change. It helps doctors understand the right dose for future patients.
Denver, ColoradoAges 18 years+ - NCT07300943RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug (an ATR inhibitor) for people with advanced solid tumors that have not responded to or are not suitable for standard treatments. It aims to see if the drug is safe and effective, and it may be an option if you have good heart function and are feeling well enough to participate.
Boston, MassachusettsAges 18 years+ - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Sacramento, CaliforniaAges 18 years+ - NCT06365840RecruitingPhase 2
Study of IMC-001 for advanced tumors with high mutations
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
GoyangAges 19 years+ - NCT04855656RecruitingPhase 1
Lunresertib for advanced solid tumors with specific gene changes
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT06878612RecruitingPhase 1
Personalized tumor cell vaccine for advanced solid tumors
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
Chengdu, SichuanAges 18–65 - NCT06927297RecruitingPhase 1
Safety study of a mitochondrial vaccine for advanced solid tumors
This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.
Chengdu, SichuanAges 18–75 - NCT05906862RecruitingPhase 1
AMT-253 for advanced solid tumors after standard treatments
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
Sydney, New South WalesAges 18 years+ - NCT06985355RecruitingPhase 1/Phase 2
Testing MHB046C injection for advanced solid tumors
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07596693RecruitingPhase 1
KXV01 injection for advanced solid tumors
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
ShanghaiAges 18–70 - NCT06487455RecruitingPhase 1
SPH7485 tablets for advanced solid tumors
This phase 1 trial tests a new oral drug called SPH7485 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
ChangshaAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT07296341RecruitingPhase 1/Phase 2
HRS-4642 plus other therapies for pancreatic cancer
This study tests an experimental drug (HRS-4642) combined with other cancer treatments for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT06598371RecruitingPhase 1/Phase 2
Study of engineered immune cells for advanced solid tumors
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
Houston, TexasAges 18 years+ - NCT06329206RecruitingPhase 1
GH2616 tablet for advanced solid tumors
This trial tests an experimental tablet, GH2616, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ZhejiangAges 18 years+
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patients with advanced solid tumors?
- Yes. Clin2 currently lists 1,061 recruiting patients with advanced solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patients with advanced solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patients with advanced solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Advanced Solid Tumor
- Advanced Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.